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Abstract: The mechanism of thrombocytopenia in dengue virus infection remains unknown. We report herein an
imported case of a 21-year-old male Japanese with dengue fever caused by secondary dengue 2 virus infection. The
thrombocytopenia detected around the day of defervescence was associated with an increased level of platelet-
associated IgG (PAIgG). The eluate from the platelets during the acute phase of this case contained an increased ac-
tivity of anti-dengue virus 2 IgG, while the eluate from platelets during the convalescent phase contained a low
level of anti-dengue 2 IgG. These findings suggest the transient formation of PAIgG involving anti-dengue 2 virus
IgG during the acute phase of secondary dengue 2 virus infection.
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INTRODUCTION
The geographical distribution of the dengue viruses, a
mosquito-borne human viral pathogen, has expanded
greatly and the number of cases has dramatically increased
over the past three decades (Igarashi, 1997). Two and a half
billion people in more than one hundred countries are cur-
rently at risk of infection, with an estimated 50 million in-
fections per year (Guzman and Kouri, 2002). The four sero-
types of dengue virus induce a wide spectrum of clinical
manifestations, which are frequently associated with throm-
bocytopenia and hemorrhagic diathesis (Srichaikul and
Nimmannitya, 2000). We recently demonstrated a correla-
tion between increased platelet-associated IgG (PAIgG) and
thrombocytopenia and the association of anti-dengue virus
IgG on platelets from patients during the acute phase of sec-
ondary dengue infection. As a result if these findings, we
propose and that PAIgG formation involving anti-dengue
virus IgG plays a pivotal role in the induction of transient
thrombocytopenia (Oishi, 2003). However, the issue of
whether the association of anti-dengue virus IgG on the
platelets is specific for the acute phase has not been deter-
mined. We demonstrate herein the acute phase-specific as-
sociation of anti-dengue virus IgG on platelets from an im-
ported case of dengue fever.
A 21-year-old Japanese man visited to the Solomon is-
lands between August 19 th and September 2 nd. Immedi-
ately after returning to Japan on September 4 th, he was ad-
mitted to Nagasaki University hospital on September 5 th,
2001 because of high fever that persisted for 2 days. His
medical examination was unremarkable except for the fever
(38.4°C) on admission. No bleeding diathesis was noted. A
thick film of his blood sample, taken on September 5 th,
was negative for the malaria parasite. A plasma sample, ob-
tained on the day of admission, was found to be positive for
dengue virus serotype 2, but negative for dengue virus sero-
types 1, 3 and 4 by RT-PCR (Morita et al, 1991). IgM cap-
ture ELISA was negative on September 5 th, but became
positive on September 14 th (Bundo et al, 1985). Parenteral
fluid therapy (5% glucose in physiological saline) was
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started on the day of admission. Acetaminphen (200 mg per
dose) was orally given when his body temperature reached
in excess of 39°C. The peripheral white blood count de-
creased on September 7 th and 9 th. More Importantly, his
peripheral platelet counts decreased on September 9 th and
reached to a minimum (49 x 10３/ml). A small amount of
epistaxis was noted on September 9 th and11th. The day of
defervescence was September 10 th. This case was diag-
nosed as dengue fever based on the WHO criteria because
the hematocrit increase was less than 20% (WHO, 1997).
Further HI tests using serum samples at the acute (Septem-
ber 8 th; 1: 40) and convalescent phase (September 19 th; 1:
5, 120) confirmed the existence of a secondary infection
(WHO, 1997).
An increased level of PAIgG (49.4 ng/ 10７ platelets;
the normal range is below 20 ng/ 10７ platelets) was found
on September 10 th when the peripheral platelet count was
the lowest. The levels of fibrin degradation product and fi-
brinogen were 2.3 µg/ml and 256 mg/dl, respectively. The
prothrombin time ratio (divided by the normal value) was
1.14. Consequently, the total disseminated intravascular co-
agulation (DIC) score was determined to be 5, which is sug-
gestive of a low probability of DIC (Nishiyama et al, 2000).
Our recent paper demonstrated that PAIgG contains anti-
dengue virus IgG during the acute phase of secondary den-
gue virus infection. We thus compared the levels of anti-
dengue virus serotype 2 IgG in between the eluted sample
from platelets on September 12 (acute phase; platelet count
is 63 x 10３/µl) and on October 23 th, 2001 (convalescent
phase; platelet count is 241 x 10３/µl). We also employed
platelet samples from three healthy volunteers (platelet
count ranges from 195 to 303 x 10３/µl). The elution of IgG
from platelet samples was carried out according to previ-
ously described procedures and the eluate was dialyzed
against phosphate buffered saline (PBS) and concentrated to
a final volume of 1ml with 1.5 x 10９ platelets (Oishi et al,
2003). The eluates (1:5 diluted in PBS) were used in an in-
direct ELISA as previously described (Oishi et al, 2003).
The optical density (OD at 405 nm; the values are the mean
of three determinations) was measured. The OD at 405 nm
of the anti-dengue 2 IgG in the eluates from the three
healthy volunteers was 0.12 ± 0.07. In contrast, an in-
creased activity of anti-dengue virus 2 IgG (OD at 405 nm;
0.98 ± 0.06) in the eluate at the acute phase of the pre-
sented case was found. A decreased activity of anti-dengue
2 IgG (OD at 405 nm; 0.19 ± 0.01) was also found in the
eluate at the convalescent phase of this patient.
The imported case of dengue fever presented in this
study was a secondary infection and was due to a dengue 2
virus infection. A transient increase in anti-dengue virus
IgG on the surface of platelets was found to be associated
with an increased level of PAIgG during the acute phase of
this case. These data support our hypothesis that the tran-
sient formation of PAIgG could be one of the important fac-
tors inducing thrombocytopenia during the acute phase of
secondary infection. Furthermore, an in vitro study has re-
ported that the dengue 2 virus binds to platelets in the pres-
ence of a virus specific antibody (Wang et al, 1995). The
authors suggest that the Fc receptor is not involved in the
antibody-dependent binding of the dengue 2 virus to plate-
lets. The fact that plasma viremia emerges, peaks during the
early phase and then disappears around the time of defer-
vesence (Libraty et al, 2002), indicates the immune com-
plexes could be formed on the platelet via the direct binding
of a virus to the platelets in the present case of dengue fever.
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